Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac for Cachexia in Advanced Pancreatic Cancer
NCT05336266Phase 1Active, not recruiting
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketorolac in cachexia. Primary endpoint: Feasibility of Ketorolac Treatment at 6 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
ketorolac
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT05336266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336266.